Research Progress on Berberine Regulating the NLRP3 Inflammasome, Gut Microbiota and Intestinal Epithelial Barrier to Improve Inflammatory Bowel Disease

Berberine (BBR) is a natural alkaloid with multi-target pharmacological activity. In recent years its potential therapeutic value in inflammatory bowel disease (IBD) has received wide attention. To sort out systematically the pharmacological mechanisms by which BBR improves IBD, this study searched PubMed, Web of Science and CNKI for the literature from 2015 to 2025, focusing on basic research, systematic reviews, meta-analyses and clinical studies, and analyzed three mechanistic axes, the NLRP3 inflammasome, the gut microbiota and the intestinal epithelial barrier. The interaction among the three drew our attention. Current evidence shows that BBR can inhibit the NF-κB/NLRP3 signaling pathway and related pyroptosis, thereby reducing intestinal inflammatory response; it can also reshape gut microbiota structure, promote the recovery of beneficial bacteria and regulate microbial metabolites; in addition, BBR can upregulate tight junction protein expression, promote epithelial regeneration and mucosal repair, and thereby improve intestinal epithelial barrier function. The three axes are not independent of each other but interrelated and mutually reinforcing, forming a synergistic network centered on inflammation inhibition, microbiota recovery and barrier repair. At the clinical level, preliminary evidence from ulcerative colitis (UC) suggests that BBR combined with 5-aminosalicylic acid (5-ASA) may have some adjunctive therapeutic value, but high-quality, large-sample, multicenter randomized controlled trials (RCTs) are still insufficient. In general, BBR shows multi-target pharmacological action in IBD treatment, but its clinical efficacy and long-term safety still need further verification.

Authors

Institutions

Publication Details

Journal
Theoretical and Natural Science
Published
2026-11-17
DOI
https://doi.org/10.54254/2753-8818/2026.es39048
Primary Topic
Berberine and alkaloids research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Research Progress on Berberine Regulating the NLRP3 Inflammasome, Gut Microbiota and Intestinal Epithelial Barrier to Improve Inflammatory Bowel Disease

Shengyu Huang
4 links
Theoretical and Natural Science
Berberine and alkaloids research
article

Research Progress on Berberine Regulating the NLRP3 Inflammasome, Gut Microbiota and Intestinal Epithelial Barrier to Improve Inflammatory Bowel Disease

Shengyu Huang
article en

Abstract

Berberine (BBR) is a natural alkaloid with multi-target pharmacological activity. In recent years its potential therapeutic value in inflammatory bowel disease (IBD) has received wide attention. To sort out systematically the pharmacological mechanisms by which BBR improves IBD, this study searched PubMed, Web of Science and CNKI for the literature from 2015 to 2025, focusing on basic research, systematic reviews, meta-analyses and clinical studies, and analyzed three mechanistic axes, the NLRP3 inflammasome, the gut microbiota and the intestinal epithelial barrier. The interaction among the three drew our attention. Current evidence shows that BBR can inhibit the NF-κB/NLRP3 signaling pathway and related pyroptosis, thereby reducing intestinal inflammatory response; it can also reshape gut microbiota structure, promote the recovery of beneficial bacteria and regulate microbial metabolites; in addition, BBR can upregulate tight junction protein expression, promote epithelial regeneration and mucosal repair, and thereby improve intestinal epithelial barrier function. The three axes are not independent of each other but interrelated and mutually reinforcing, forming a synergistic network centered on inflammation inhibition, microbiota recovery and barrier repair. At the clinical level, preliminary evidence from ulcerative colitis (UC) suggests that BBR combined with 5-aminosalicylic acid (5-ASA) may have some adjunctive therapeutic value, but high-quality, large-sample, multicenter randomized controlled trials (RCTs) are still insufficient. In general, BBR shows multi-target pharmacological action in IBD treatment, but its clinical efficacy and long-term safety still need further verification.

Theoretical and Natural ScienceVol. 200(1)
Peking University (CN)
Good health and well-being
Berberine and alkaloids research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon